Serum potassium and adverse outcomes across the range of kidney function: a chronic kidney disease (CKD) Prognosis Consortium meta-analysis
Authors' conclusion
Outpatient potassium levels both above and below the normal range are consistently associated with adverse outcomes, with similar risk relationships across eGFR and albuminuria.
Study context
- Population
- Participants of 27 international cohorts (general population, high CV risk, CKD) across the range of kidney function
- Participants
- 1,217,986 participants27 cohorts
- Comparison
- Serum potassium levels vs reference 4.2 mmol/L
- Outcome
- All-cause mortality, CV mortality and end-stage renal disease
- Follow-up
- Mean 6.9 years
Methodological detailsrandom-effects meta-analysis, CKD Prognosis Consortium
- Random-effects meta-analysis
- CKD Prognosis Consortium
Pooled result
As reported in the abstract
All-cause mortality
Adjusted hazard ratio (95% CI)
5.5 mmol/Lvs 4.2 mmol/L
1.22(1.15–1.29)
3.0 mmol/Lvs 4.2 mmol/L
1.49(1.26–1.76)
Further pooled results
Risk by estimated glomerular filtration rate (eGFR), albuminuria, RAAS inhibitor use and cohort
- Risks were similar by eGFR, albuminuria, RAAS inhibitor use and across cohorts
Serum potassium >5.5 mmol/L
- Related to lower eGFR and higher albuminuria
Original publication
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. Published 14 March 2018. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →